Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 453

Results For "NAL"

5935 News Found

Lonza signs manufacturing agreement with Oasmia Pharmaceutical
News | March 21, 2022

Lonza signs manufacturing agreement with Oasmia Pharmaceutical

Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply


Tata Elxsi has unveiled TEngage, a digital health platform
Digitisation | March 19, 2022

Tata Elxsi has unveiled TEngage, a digital health platform

In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check


Govt to deploy Truenat platform for TB screening across India
News | March 19, 2022

Govt to deploy Truenat platform for TB screening across India

It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour


Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug
Drug Approval | March 19, 2022

Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug

The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis


Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine
News | March 19, 2022

Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine

Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships


Manipal Hospitals deploys wearable technology to monitor post-surgery care
Hospitals | March 19, 2022

Manipal Hospitals deploys wearable technology to monitor post-surgery care

Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud


Merck discontinues KEYLYNK-101 trial to treat prostate cancer
Biotech | March 18, 2022

Merck discontinues KEYLYNK-101 trial to treat prostate cancer

At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide


Thirty five generic manufacturers sign agreements with MPP for Paxlovid
News | March 18, 2022

Thirty five generic manufacturers sign agreements with MPP for Paxlovid

The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris


AstraZeneca launches global R&D post-doctoral challenge
News | March 18, 2022

AstraZeneca launches global R&D post-doctoral challenge

Successful proposals will secure fully funded postdoctoral research positions


Health Canada authorizes Moderna's COVID-19 vaccine in children (6-11 Years)
News | March 18, 2022

Health Canada authorizes Moderna's COVID-19 vaccine in children (6-11 Years)

The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years